HCV-TARGET: DAA regimens safe, effective in LT, KT recipients

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • HCV treatment with direct-acting antivirals (DAAs) is safe and effective in liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) transplant recipients.

Why this matters

  • Real-world cohorts reflect a more diverse population than clinical trials.

Study d...